This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Invaron Pharmaceuticals And The Center For Assisted Reproduction (CARE) Initiate Investigator Led Phase III Clinical Study On INVOcell(TM)

BEDFORD, TX, Feb. 28, 2013 /PRNewswire/ - Invaron Pharmaceuticals Inc. clinical partner, the Center for Assisted Reproduction (CARE), led by Kevin Doody M.D., today initiated an investigator led, IRB approved Phase III study using INVOcell TM in patients with tubal blockage or unexplained infertility that require in vitro fertilization.

INVOcell TM is an innovative medical device used in infertility treatment which enables conception and early embryo development to occur within a woman's own body rather than in a laboratory.  "The primary focus of the study will be to first evaluate the comfort and retention of the system over 5 days to ensure that INVOcell TM performs similarly to existing 3 day retention data," remarked Dr. Kevin Doody.  "We will then examine how INVOcell TM compares to conventional IVF in an open label extension, examining the quality day 5 embryos, known as blastocysts, and ultimately pregnancy and live birth rates".

"We are excited at the prospect of partnering with CARE and Dr. Kevin Doody as part of our Phase III/IV clinical program in the United States and Canada," said Jason Broome, President and COO of Invaron Pharmaceuticals.  "IVF is increasingly utilizing day 5 embryo culture and this data will ultimately serve to broaden the use of INVOcell TM".

Patients interested in learning more are encouraged to contact the Center for Assisted Reproduction in Bedford Texas directly.

About Invaron Pharmaceuticals

Invaron is a Canadian based pharmaceutical company focusing exclusively on the acquisition of niche drugs and medical devices registered in other countries but not in Canada. By facilitating local registration, bridging clinical gaps, and launching innovative marketing strategies, Invaron will effectively meet the under serviced needs of Canadian patients in a wide variety of therapeutic areas.  Invaron encourages patients, physicians, potential pharmaceutical partners and other stakeholders to visit to learn more.

About the Centre for Assisted Reproduction (CARE)

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs